This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kasibhatla, S. Articles by Tseng, B. Search for Related Content PubMed PubMed Citation Articles by Kasibhatla, S. Articles by Tseng, B. Related Collections Cellular Pathobiology Cellular Pathobiology: Proliferation, Senescence, and Death

Minireview

Why Target Apoptosis in Cancer Treatment?

Maxim Pharmaceuticals, San Diego, California 92121

¹ To whom requests for reprints should be addressed, at Maxim Pharmaceuticals, Inc., 6650 Nancy Ridge Drive, San Diego, CA 92121. Phone: (858) 202-4042; Fax: (858) 202-4000; E-mail: skasibhatla{at}maxim.com

Defective apoptosis (programmed cell death) represents a major causative factor in the development and progression of cancer. The ability of tumor cells to evade engagement of apoptosis can play a significant role in their resistance to conventional therapeutic regimens. Our understanding of the complexities of apoptosis and the mechanisms evolved by tumor cells to resist engagement of cell death has focused research effort into the development of strategies designed to selectively induce apoptosis in cancer cells. This article will review the underlying mechanisms of apoptosis and the ways in which tumor cells modulate these processes to promote their survival and evaluate the efficacy of current clinical approaches aimed at exploiting these defects to selectively induce apoptosis in tumor cells.

This article has been cited by other articles:

				S. Kasibhatla, V. Baichwal, S. X. Cai, B. Roth, I. Skvortsova, S. Skvortsov, P. Lukas, N. M. English, N. Sirisoma, J. Drewe, et al. MPC-6827: A Small-Molecule Inhibitor of Microtubule Formation That Is Not a Substrate for Multidrug Resistance Pumps Cancer Res., June 15, 2007; 67(12): 5865 - 5871. [Abstract] [Full Text] [PDF]

				E. C. LACASSE, E. R. KANDIMALLA, P. WINOCOUR, T. SULLIVAN, S. AGRAWAL, J. W. GILLARD, and J. DURKIN Application of XIAP Antisense to Cancer and Other Proliferative Disorders: Development of AEG35156/ GEM(R)640 Ann. N.Y. Acad. Sci., November 1, 2005; 1058(1): 215 - 234. [Abstract] [Full Text] [PDF]

				S. Kasibhatla, K. A. Jessen, S. Maliartchouk, J. Y. Wang, N. M. English, J. Drewe, L. Qiu, S. P. Archer, A. E. Ponce, N. Sirisoma, et al. A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid PNAS, August 23, 2005; 102(34): 12095 - 12100. [Abstract] [Full Text] [PDF]

				K. A. Jessen, N. M. English, J. Yu Wang, S. Maliartchouk, S. P. Archer, L. Qiu, R. Brand, J. Kuemmerle, H.-Z. Zhang, K. Gehlsen, et al. The discovery and mechanism of action of novel tumor-selective and apoptosis-inducing 3,5-diaryl-1,2,4-oxadiazole series using a chemical genetics approach Mol. Cancer Ther., May 1, 2005; 4(5): 761 - 771. [Abstract] [Full Text] [PDF]

				M. Kaur, C. Agarwal, R. P. Singh, X. Guan, C. Dwivedi, and R. Agarwal Skin cancer chemopreventive agent, {alpha}-santalol, induces apoptotic death of human epidermoid carcinoma A431 cells via caspase activation together with dissipation of mitochondrial membrane potential and cytochrome c release Carcinogenesis, February 1, 2005; 26(2): 369 - 380. [Abstract] [Full Text] [PDF]

				S. Kasibhatla, H. Gourdeau, K. Meerovitch, J. Drewe, S. Reddy, L. Qiu, H. Zhang, F. Bergeron, D. Bouffard, Q. Yang, et al. Discovery and mechanism of action of a novel series of apoptosis inducers with potential vascular targeting activity Mol. Cancer Ther., November 1, 2004; 3(11): 1365 - 1374. [Abstract] [Full Text] [PDF]

				V. M. Adhami, M. H. Aziz, S. R. Reagan-Shaw, M. Nihal, H. Mukhtar, and N. Ahmad Sanguinarine causes cell cycle blockade and apoptosis of human prostate carcinoma cells via modulation of cyclin kinase inhibitor-cyclin-cyclin-dependent kinase machinery Mol. Cancer Ther., August 1, 2004; 3(8): 933 - 940. [Abstract] [Full Text] [PDF]